Combined prostate cancer vaccine plus immune checkpoint inhibition synergizes to eliminate prostate cancer.
1/5 보강
Immunotherapy has improved outcomes in many cancers, yet the clinical benefits remain limited in prostate cancer.
APA
Carreno-Galeano G, Dubey S, et al. (2026). Combined prostate cancer vaccine plus immune checkpoint inhibition synergizes to eliminate prostate cancer.. iScience, 29(1), 114552. https://doi.org/10.1016/j.isci.2025.114552
MLA
Carreno-Galeano G, et al.. "Combined prostate cancer vaccine plus immune checkpoint inhibition synergizes to eliminate prostate cancer.." iScience, vol. 29, no. 1, 2026, pp. 114552.
PMID
41568144 ↗
Abstract 한글 요약
Immunotherapy has improved outcomes in many cancers, yet the clinical benefits remain limited in prostate cancer. We evaluated whether an adenovirus-based bivalent prostate cancer vaccine (Ad-PS2) targeting two tumor antigens could be strengthened by combination with immune checkpoint blockade. Using immunocompetent mouse models, we found that Ad-PS2 combined with low-dose anti-CTLA4 generated robust anti-tumor immunity capable of eliminating established tumors, exceeding the effects of either treatment alone. Tumor-free mice resisted subsequent tumor rechallenge, indicating durable immune protection. Tumor analysis revealed a significant increase in intratumor CD8 T cell infiltration with Ad-PS2 and anti-CTLA4, whereas anti-PD1 alone produced minimal infiltration and, with the vaccine, provided no therapeutic advantage. These results highlight a mechanistically synergistic interaction between dual antigen-targeted vaccination and CTLA4 blockade and illustrate how rational combination immunotherapy can overcome resistance in prostate cancer. This work defines a strategy that could inform future translational approaches for improving immunologic control of prostate cancer.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and Survival.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Microfluidic-based patient-derived organoids recapitulate thyroid cancer heterogeneity and reveal NF-κB-driven maturation for precision therapy.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.